2013
DOI: 10.3892/mco.2013.172
|View full text |Cite
|
Sign up to set email alerts
|

Glioma and glioblastoma - how much do we (not) know?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
117
0
1

Year Published

2014
2014
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 158 publications
(118 citation statements)
references
References 97 publications
0
117
0
1
Order By: Relevance
“…The prognosis of astrocytoma differs according to features such as age, disease stage, and histological type. GBM is the most malignant astrocytoma, with a median overall survival (OS) of approximately 12 months and a 5‐year OS of 4.8%‐5.4%,1, 2, 3 while patients suffering from anaplastic astrocytoma have a median OS of 38 months and a 5‐year OS of 25.9%‐41.1% 1, 4. A deeper understanding of the prognostic factors of GBM may provide new ideas for the prevention and management of this disease.…”
Section: Introductionmentioning
confidence: 99%
“…The prognosis of astrocytoma differs according to features such as age, disease stage, and histological type. GBM is the most malignant astrocytoma, with a median overall survival (OS) of approximately 12 months and a 5‐year OS of 4.8%‐5.4%,1, 2, 3 while patients suffering from anaplastic astrocytoma have a median OS of 38 months and a 5‐year OS of 25.9%‐41.1% 1, 4. A deeper understanding of the prognostic factors of GBM may provide new ideas for the prevention and management of this disease.…”
Section: Introductionmentioning
confidence: 99%
“…Patients diagnosed with astrocytoma grade III and GBM have a 5-year median survival rate of 26.5% and 4.7%, respectively (Ostrom et al, 2013). The extremely low survival rate of GBM patients is caused by high levels of invasion of tumorogenic cells into the surrounding tissue and high resistance to therapies (Jovčevska et al, 2013). Current median survival rates, when compared with those in 1995-1998, have increased by approximately 4 months (Mazaris et al, 2014).…”
Section: Introductionmentioning
confidence: 99%
“…In the past decade, the median survival of glioma patients has remained stable at 12 months or less (2). Previous studies on glioma mostly have focused on histopathology and molecular biology, and few have aimed at the systematic investigation of the correlation between tumor cell phenotype and the function nature in tumor tissue (3).…”
Section: Introductionmentioning
confidence: 99%